How commonly do transaminase levels rise with tigecycline use?

How often do liver enzymes rise during tigecycline treatment?

Transaminase elevations occur in roughly 5–7 % of patients given tigecycline, a rate similar to most broad-spectrum antibiotics.

How do the numbers look in controlled trials versus everyday use?

Pooled data from 3,500+ participants across registration studies showed ALT increases in 5.4 % and AST increases in 4.8 % of tigecycline recipients. Post-marketing surveillance and smaller hospital cohorts report comparable or slightly higher rates, up to 9 % in critically ill patients.

Which patient groups see more frequent rises?

Patients with pre-existing liver disease, those receiving prolonged courses (>14 days), and individuals on multiple hepatotoxic drugs experience higher rates. In one ICU series, baseline cirrhosis doubled the odds of a clinically significant ALT spike.

What thresholds trigger concern or dose change?

Clinicians generally watch for ALT or AST values exceeding three times the upper limit of normal. Most rises stay below this cutoff and resolve after stopping or switching therapy; discontinuation for liver-test abnormalities occurs in about 1 % of treated patients.

How does tigecycline compare with other tetracyclines or last-resort antibiotics?

Minocycline and doxycycline cause transaminase elevations in 2–4 % of recipients. In head-to-head studies with vancomycin or linezolid, tigecycline’s liver-signal was numerically higher but rarely reached statistical significance.

When do the elevations usually appear and resolve?

Most laboratory changes are detected within the first week of therapy and return to baseline within 7–14 days after drug cessation. Persistent elevations beyond two weeks prompt evaluation for other causes.

Are there regulatory warnings or monitoring recommendations?

The FDA label advises baseline and periodic liver-function tests, especially in patients with hepatic impairment. No specific boxed warning exists for hepatotoxicity, but the label notes that severe hepatic reactions, including acute liver failure, have been reported rarely.

What alternatives exist if transaminases climb?

Switching to an agent with a lower hepatic risk profile—such as a beta-lactam/beta-lactamase inhibitor combination or a fluoroquinolone—remains the most common strategy. Dose adjustment is not recommended; the drug is discontinued if clinically significant liver injury develops.

How do patents and generic availability affect access to alternatives?

Tygacil (tigecycline) lost U.S. exclusivity in 2021. Several generic versions are now marketed, lowering cost and prompting some hospitals to retain tigecycline on formulary despite its hepatic signal. DrugPatentWatch lists current patent and exclusivity records for tigecycline products.